{
    "clinical_study": {
        "@rank": "147926", 
        "acronym": "SAPIEN3", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and device success of the Edwards SAPIEN 3\n      Transcatheter Heart Valve (S3 THV) and the Edwards Commander and Certitude Delivery Systems\n      in patients with symptomatic, severe aortic stenosis who are indicated for aortic valve\n      replacement."
        }, 
        "brief_title": "Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Valve Disease", 
        "detailed_description": {
            "textblock": "This is a non-randomized, prospective, multi-center safety and device success study. One\n      hundred fifty (150) patients are planned to be enrolled at up to 15 participating\n      investigational centers in Europe and Canada.  Patient participation will last for a minimum\n      of 5 years.  Patients will be assessed at the following intervals: baseline, hospital\n      discharge, 30 days, 1 year and annually thereafter for a minimum of 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Severe symptomatic calcific aortic valve stenosis with:\n\n               1. High surgical risk: STS Score \u2265 8 or EuroSCORE \u2265 15 (first 50 patients),\n\n               2. Intermediate surgical risk: STS Score \u2265 4 or EuroSCORE \u2265 10 (subse-quent 100\n                  patients).\n\n          2. Age \u2265 75 years.\n\n          3. NYHA \u2265 II\n\n          4. AVA< 1cm2 and mean gradient > 40mmHg\n\n          5. Heart team (including examining cardiac surgeon) agrees on eligibility including\n             assessment that TAVR is appropriate\n\n          6. Study patient has provided written informed consent to comply with all of the study\n             procedures and follow-up visits\n\n        Exclusion Criteria:\n\n          1. Non-calcified aortic valve\n\n          2. Acute myocardial infarction \u2264 30 days before the intended treatment\n\n          3. Untreated clinically significant coronary artery disease requiring revascularization.\n\n          4. Aortic valve is a congenital unicuspid or congenital bicuspid valve.\n\n          5. Mixed aortic valve disease (with predominant aortic regurgitation)\n\n          6. Preexisting bioprosthetic valve or ring in any position\n\n          7. Leukopenia, anemia, thrombocytopenia\n\n          8. Hypertrophic cardiomyopathy with or without obstruction\n\n          9. Severe ventricular dysfunction with LVEF < 20%\n\n         10. Echocardiographic evidence of intracardiac mass, thrombus or vegetation\n\n         11. Active upper GI bleeding within 90 days prior to procedure\n\n         12. known contraindication or hypersensitivity to all anticoagulation regimens, or\n             inability to be anticoagulated for the study procedure\n\n         13. Native aortic annulus size :\n\n               1. < 18 mm or > 25 mm as measured by TEE, 23 and 26mm valves\n\n               2. > 27mm as measured by TEE, 29mm valve\n\n               3. < 16mm as measured by TEE, 20mm valve\n\n         14. Clinically (by neurologist) or neuroimaging confirmed stroke or TIA within 90 days of\n             the procedure\n\n         15. Renal insufficiency (creatinine > 3.0 mg/dL) and/or renal replacement therapy at the\n             time of screening\n\n         16. Estimated life expectancy < 24 months\n\n         17. Expectation that patient will not improve despite treatment of aortic stenosis\n\n         18. Currently participating in an investigational drug or another device study\n\n         19. Active bacterial endocarditis within 180 days of procedure\n\n         20. Known hypersensitivity to contrast media, nitinol (nickel or titanium)\n\n         21. Any neurologic disease which severely affects the ability to walk or perform everyday\n             activities\n\n         22. Senile dementia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "75 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808287", 
            "org_study_id": "2012-07"
        }, 
        "intervention": {
            "description": "The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (interme-diate or higher operable risk) with severe aortic stenosis re-quiring aortic valve replacement (AVR).", 
            "intervention_name": "Edwards SAPIEN 3 Transcatheter Heart Valve", 
            "intervention_type": "Device", 
            "other_name": [
                "TAVR", 
                "TAVI"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Transcatheter Aortic Valve Replacement", 
            "Aortic Stenosis"
        ], 
        "lastchanged_date": "September 27, 2013", 
        "location": [
            {
                "contact": {
                    "email": "webb@providencehealth.bc.ca", 
                    "last_name": "John Webb, MD", 
                    "phone": "+1 604 806 8902"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V6Z 1 Y6"
                    }, 
                    "name": "St. Paul's Hospital"
                }, 
                "investigator": {
                    "last_name": "John Webb, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "helene.eltchaninoff@chu-rouen.fr", 
                    "last_name": "Helene Eltchaninoff, MD", 
                    "phone": "+33 2 32 88 86 25"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76031"
                    }, 
                    "name": "CHU Charles Nicolle"
                }, 
                "investigator": {
                    "last_name": "Helene Eltchaninoff, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dumonteil.n@chu-toulouse.fr", 
                    "last_name": "Nicolas Dumonteil, MD", 
                    "phone": "+33561323548"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHU Rangueil"
                }, 
                "investigator": {
                    "last_name": "Nicolas Dumonteil, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "T.Walther@kerckhoff-klinik.de", 
                    "last_name": "Prof. Dr. Thomas Walther, MD", 
                    "phone": "+49 6032 996 2501"
                }, 
                "facility": {
                    "address": {
                        "city": "Bad Nauheim", 
                        "country": "Germany", 
                        "zip": "61231"
                    }, 
                    "name": "Kerckhoff Heartcenter"
                }, 
                "investigator": {
                    "last_name": "Prof. Dr. Thomas Walther, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Matthias.Thielmann@uk-essen.de", 
                    "last_name": "Matthias Thielmann, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45122"
                    }, 
                    "name": "Universitatsklinik Essen"
                }, 
                "investigator": {
                    "last_name": "Matthias Thielmann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "treede@uke.de", 
                    "last_name": "Hendrick Treede, MD", 
                    "phone": "+49 40 7410 58949"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20251"
                    }, 
                    "name": "Universitares Herzzentrum Hamburg GmbH"
                }, 
                "investigator": {
                    "last_name": "Hendrick Treede, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gerhard.schymik@klinikum-karlsruhe.de", 
                    "last_name": "Gerhard Schymik, MD", 
                    "phone": "+49 721 974 29 10"
                }, 
                "facility": {
                    "address": {
                        "city": "Karlsruhe", 
                        "country": "Germany", 
                        "zip": "76133"
                    }, 
                    "name": "Stadtisches Klinikum Kalsruhe"
                }, 
                "investigator": {
                    "last_name": "Gerhard Schymik, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "thorsten.wahlers@uk-koeln.de", 
                    "last_name": "Thorsten Wahlers, MD", 
                    "phone": "+49221 478 32507"
                }, 
                "facility": {
                    "address": {
                        "city": "Koln", 
                        "country": "Germany", 
                        "zip": "50937"
                    }, 
                    "name": "Universitatsklinik Koln"
                }, 
                "investigator": {
                    "last_name": "Thorsten Wahlers, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "giuseppe.tarantini.1@unipd.it", 
                    "last_name": "Giuseppe Tarantini, MD", 
                    "phone": "+39 049821 2585"
                }, 
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "zip": "35128"
                    }, 
                    "name": "Policlinico Universitario"
                }, 
                "investigator": {
                    "last_name": "Giuseppe Tarantini, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marks.spence@belfasttrust.hscni.net; markspence1@yahoo.co.uk", 
                    "last_name": "Mark Spence, MD", 
                    "phone": "+44 7710475449"
                }, 
                "facility": {
                    "address": {
                        "city": "Belfast", 
                        "country": "United Kingdom", 
                        "zip": "BT12 6BA"
                    }, 
                    "name": "Royal Victoria Hospital"
                }, 
                "investigator": {
                    "last_name": "Mark Spence, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "olaf.wendler@gstt.nhs.uk", 
                    "last_name": "Olaf Wendler, MD", 
                    "phone": "+44 203 299 4341"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "King's College Hospital"
                }, 
                "investigator": {
                    "last_name": "Olaf Wendler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "martyn.thomas@gstt.nhs.uk; mttwins@aol.com", 
                    "last_name": "Martyn Thomas, MD", 
                    "phone": "+44 207 188 10 97"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE1 7EH"
                    }, 
                    "name": "London St. Thomas's Hospital"
                }, 
                "investigator": {
                    "last_name": "Martyn Thomas, MD`", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "MichaeI.Mullen@uclh.nhs.uk", 
                    "last_name": "Michael Mullen, MD", 
                    "phone": "+44 207 504 8801"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W1G 8PH"
                    }, 
                    "name": "The London Heart Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Mullen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "malcolm@dalrymple-hay.com", 
                    "last_name": "Dalrymple-Hay, MD", 
                    "phone": "+44 1752 439231"
                }, 
                "facility": {
                    "address": {
                        "city": "Plymouth", 
                        "country": "United Kingdom", 
                        "zip": "PL6 8DH"
                    }, 
                    "name": "Derriford Hospital"
                }, 
                "investigator": {
                    "last_name": "mple-Hay, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "France", 
                "Germany", 
                "Italy", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve", 
        "overall_contact": {
            "email": "jodi_akin@edwards.com", 
            "last_name": "Jodi Akin, MSN", 
            "phone": "949-250-2730"
        }, 
        "overall_contact_backup": {
            "email": "ihsen_merioua@edwards.com", 
            "last_name": "Ishen Merioua, MD", 
            "phone": "+41 44 787 4456"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Denmark: Danish Health and Medicines Authority", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "NAP", 
            "measure": "All-cause mortality rate", 
            "safety_issue": "Yes", 
            "time_frame": "30 days post-index procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808287"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "device success\nabsence of procedural mortality AND correct positioning of a single THV and intended performance of the THV\nsafety endpoints\ncomposite of mortality, and major complications including THV-related dysfunction major bleeds MI new conduction abnormality new onset of AF time-related valve safety compo-site of valve structural deterioration composite of all-cause mortality, all stroke, re-hospitalization for valve-related symptoms or worsening CHF rehospitalization for valve cause NYHA class 6 MWT QoL Hospital length of stay\nechocardiography endpoints\nPVL & total valve regurgitation prostetic valve dysfunction IEOA mean aortic valve gradient structural valve deterioration LVEF", 
            "measure": "device success(VARC II) safety endpoints(VARC II) echocardiography endpoints(VARCII)", 
            "safety_issue": "Yes", 
            "time_frame": "Discharge or 72 hours (whichever is longer), 30 days, 1 and 5 years post-index procedure."
        }, 
        "source": "Edwards Lifesciences", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Medstar Research Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "European Cardiovascular Research  Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of British Columbia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Edwards Lifesciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}